MEPs voted to adopt their negotiating position on the controversial reform, but it will not be finalised until after the European elections in June. Despite concessions, the pharma industry is not happy
After long negotiations MEPs agreed on the EU’s pharmaceutical reform. It includes longer exclusivity for data filed to get marketing approval for new drugs. But pharma still isn’t happy
Clinical research backed by the EU is bringing life-saving medicines and health tools to sub-Saharan Africa. This success story offers a valuable lesson as negotiations get underway on the next research programme
It is promised as the most important update for more than twenty years, but tensions are high as MEPs struggle to reach a compromise over the EU’s proposed pharmaceutical reform
Research commissioned by lobby group EFPIA shows Germany, Belgium and France will be among those hit hardest if the Commission’s proposals go ahead. In total, R&D would be cut by €2B per annum
Forty new rare disease programmes entering the clinic over the next decade. This is the goal of a new collaboration between Oxford University and the Harrington Discovery Institute, which aims to put up to £200M into getting projects out academic labs and into clinical development
Long-awaited Commission proposals to reform EU’s pharmaceutical legislation seek to improve access to medicines and promote innovation, but companies say they will drive investment out of Europe
Already overdue, the new pharmaceutical strategy will not be published tomorrow as promised. The Commission says the proposal will arrive ‘slightly later’, as tensions fly high over how to incentivise industrial R&D
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.